End-of-day quote
Shanghai S.E.
23:00:00 05/05/2024 BST
|
5-day change
|
1st Jan Change
|
16.92
CNY
|
+2.98%
|
|
+6.75%
|
-0.53%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
22,407
|
22,807
|
25,516
|
23,326
|
23,238
|
18,814
|
Enterprise Value (EV)
1 |
22,964
|
23,309
|
27,111
|
25,150
|
23,660
|
20,917
|
P/E ratio
|
11.9
x
|
11.8
x
|
13.7
x
|
18.1
x
|
-14
x
|
59
x
|
Yield
|
4.91%
|
7.83%
|
2.28%
|
1.71%
|
4.57%
|
-
|
Capitalization / Revenue
|
1.64
x
|
1.6
x
|
1.59
x
|
1.48
x
|
1.55
x
|
1.42
x
|
EV / Revenue
|
1.68
x
|
1.64
x
|
1.69
x
|
1.6
x
|
1.58
x
|
1.58
x
|
EV / EBITDA
|
11.3
x
|
9.32
x
|
10
x
|
12.2
x
|
11.3
x
|
11.6
x
|
EV / FCF
|
37.1
x
|
15.3
x
|
31.2
x
|
27.5
x
|
12.1
x
|
-48.7
x
|
FCF Yield
|
2.69%
|
6.51%
|
3.21%
|
3.64%
|
8.26%
|
-2.05%
|
Price to Book
|
1.62
x
|
1.67
x
|
1.86
x
|
1.62
x
|
1.88
x
|
1.62
x
|
Nbr of stocks (in thousands)
|
1,152,242
|
1,106,043
|
1,106,043
|
1,106,043
|
1,106,043
|
1,106,043
|
Reference price
2 |
19.45
|
20.62
|
23.07
|
21.09
|
21.01
|
17.01
|
Announcement Date
|
25/04/19
|
27/04/20
|
28/04/21
|
27/04/22
|
28/04/23
|
25/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
13,665
|
14,255
|
16,007
|
15,763
|
14,951
|
13,245
|
EBITDA
1 |
2,036
|
2,500
|
2,709
|
2,059
|
2,100
|
1,802
|
EBIT
1 |
1,823
|
2,276
|
2,287
|
1,741
|
1,776
|
1,225
|
Operating Margin
|
13.34%
|
15.96%
|
14.29%
|
11.04%
|
11.88%
|
9.25%
|
Earnings before Tax (EBT)
1 |
2,255
|
2,415
|
2,361
|
1,714
|
-1,387
|
394.6
|
Net income
1 |
1,888
|
1,946
|
1,861
|
1,289
|
-1,657
|
319
|
Net margin
|
13.82%
|
13.65%
|
11.63%
|
8.18%
|
-11.08%
|
2.41%
|
EPS
2 |
1.639
|
1.744
|
1.682
|
1.166
|
-1.498
|
0.2884
|
Free Cash Flow
1 |
618.6
|
1,519
|
870
|
915.4
|
1,955
|
-429.3
|
FCF margin
|
4.53%
|
10.65%
|
5.44%
|
5.81%
|
13.08%
|
-3.24%
|
FCF Conversion (EBITDA)
|
30.39%
|
60.74%
|
32.11%
|
44.46%
|
93.11%
|
-
|
FCF Conversion (Net income)
|
32.76%
|
78.03%
|
46.75%
|
71%
|
-
|
-
|
Dividend per Share
2 |
0.9550
|
1.614
|
0.5260
|
0.3600
|
0.9600
|
-
|
Announcement Date
|
25/04/19
|
27/04/20
|
28/04/21
|
27/04/22
|
28/04/23
|
25/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
558
|
503
|
1,595
|
1,823
|
422
|
2,104
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.274
x
|
0.201
x
|
0.5887
x
|
0.8855
x
|
0.2009
x
|
1.167
x
|
Free Cash Flow
1 |
619
|
1,519
|
870
|
915
|
1,955
|
-429
|
ROE (net income / shareholders' equity)
|
14.1%
|
14.2%
|
13.4%
|
8.74%
|
-12.9%
|
1.28%
|
ROA (Net income/ Total Assets)
|
5.81%
|
6.9%
|
6.49%
|
4.64%
|
4.83%
|
3.57%
|
Assets
1 |
32,510
|
28,191
|
28,689
|
27,772
|
-34,288
|
8,923
|
Book Value Per Share
2 |
12.00
|
12.30
|
12.40
|
13.00
|
11.20
|
10.50
|
Cash Flow per Share
2 |
1.480
|
1.650
|
1.330
|
1.100
|
1.940
|
0.6300
|
Capex
1 |
1,310
|
662
|
536
|
434
|
543
|
530
|
Capex / Sales
|
9.59%
|
4.64%
|
3.35%
|
2.75%
|
3.63%
|
4%
|
Announcement Date
|
25/04/19
|
27/04/20
|
28/04/21
|
27/04/22
|
28/04/23
|
25/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -0.53% | 2.51B | | +43.35% | 6.11B | | -15.99% | 4.35B | | -6.35% | 3.19B | | +4.87% | 3.15B | | +53.07% | 1.98B | | -3.63% | 1.74B | | +2.76% | 1.63B | | -8.02% | 1.6B | | +46.34% | 1.45B |
Alternative Medicine
|